Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels
- 浏览0
Clinical and experimental allergy
1659-1659页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



